Cargando…

Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients

Hepatitis C virus (HCV) genotype 3 is very prevalent in Europe and Asia and is associated with worst outcomes than other genotypes. Genetic factors have been associated with HCV infection; however, no extensive genome-wide study has been performed among HCV genotype 3 patients. In this study, using...

Descripción completa

Detalles Bibliográficos
Autores principales: Pedergnana, Vincent, Irving, William L., Barnes, Eleanor, McLauchlan, John, Spencer, Chris C.A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767867/
https://www.ncbi.nlm.nih.gov/pubmed/31260374
http://dx.doi.org/10.1089/jir.2019.0013
_version_ 1783455013338611712
author Pedergnana, Vincent
Irving, William L.
Barnes, Eleanor
McLauchlan, John
Spencer, Chris C.A.
author_facet Pedergnana, Vincent
Irving, William L.
Barnes, Eleanor
McLauchlan, John
Spencer, Chris C.A.
author_sort Pedergnana, Vincent
collection PubMed
description Hepatitis C virus (HCV) genotype 3 is very prevalent in Europe and Asia and is associated with worst outcomes than other genotypes. Genetic factors have been associated with HCV infection; however, no extensive genome-wide study has been performed among HCV genotype 3 patients. In this study, using a large cohort of 1,759 patients infected with HCV genotype 3, we explore the role of genetic variants on the response to interferon (IFN) and direct-acting antiviral (DAA) regimens and viremia in a combined candidate gene and genome-wide analysis. We show that genetic variants within the IFN lambda 4 (IFNL4) locus are the major factors associated with the studied traits, accordingly with observations in other HCV genotypes and with comparable effect sizes. In particular, the functional dinucleotide polymorphism rs368234815 was associated with IFN-based sustained virologic response (SVR) [odds ratio (OR) = 1.5, P = 2.3 × 10(−7)], viremia (beta = −0.23, P = 8.8 × 10(−10)), and also DAA-based SVR (OR = 1.7; P = 4.2 × 10(−4)). Our results provide evidence for a role of genetic variants on HCV viremia and SVR, notably DAA-based, in patients infected with HCV genotype 3.
format Online
Article
Text
id pubmed-6767867
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Mary Ann Liebert, Inc., publishers
record_format MEDLINE/PubMed
spelling pubmed-67678672019-10-01 Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients Pedergnana, Vincent Irving, William L. Barnes, Eleanor McLauchlan, John Spencer, Chris C.A. J Interferon Cytokine Res Research Reports Hepatitis C virus (HCV) genotype 3 is very prevalent in Europe and Asia and is associated with worst outcomes than other genotypes. Genetic factors have been associated with HCV infection; however, no extensive genome-wide study has been performed among HCV genotype 3 patients. In this study, using a large cohort of 1,759 patients infected with HCV genotype 3, we explore the role of genetic variants on the response to interferon (IFN) and direct-acting antiviral (DAA) regimens and viremia in a combined candidate gene and genome-wide analysis. We show that genetic variants within the IFN lambda 4 (IFNL4) locus are the major factors associated with the studied traits, accordingly with observations in other HCV genotypes and with comparable effect sizes. In particular, the functional dinucleotide polymorphism rs368234815 was associated with IFN-based sustained virologic response (SVR) [odds ratio (OR) = 1.5, P = 2.3 × 10(−7)], viremia (beta = −0.23, P = 8.8 × 10(−10)), and also DAA-based SVR (OR = 1.7; P = 4.2 × 10(−4)). Our results provide evidence for a role of genetic variants on HCV viremia and SVR, notably DAA-based, in patients infected with HCV genotype 3. Mary Ann Liebert, Inc., publishers 2019-10-01 2019-09-27 /pmc/articles/PMC6767867/ /pubmed/31260374 http://dx.doi.org/10.1089/jir.2019.0013 Text en © Vincent Pedergnana et al. 2019; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Reports
Pedergnana, Vincent
Irving, William L.
Barnes, Eleanor
McLauchlan, John
Spencer, Chris C.A.
Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients
title Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients
title_full Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients
title_fullStr Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients
title_full_unstemmed Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients
title_short Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients
title_sort impact of ifnl4 genetic variants on sustained virologic response and viremia in hepatitis c virus genotype 3 patients
topic Research Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767867/
https://www.ncbi.nlm.nih.gov/pubmed/31260374
http://dx.doi.org/10.1089/jir.2019.0013
work_keys_str_mv AT pedergnanavincent impactofifnl4geneticvariantsonsustainedvirologicresponseandviremiainhepatitiscvirusgenotype3patients
AT irvingwilliaml impactofifnl4geneticvariantsonsustainedvirologicresponseandviremiainhepatitiscvirusgenotype3patients
AT barneseleanor impactofifnl4geneticvariantsonsustainedvirologicresponseandviremiainhepatitiscvirusgenotype3patients
AT mclauchlanjohn impactofifnl4geneticvariantsonsustainedvirologicresponseandviremiainhepatitiscvirusgenotype3patients
AT spencerchrisca impactofifnl4geneticvariantsonsustainedvirologicresponseandviremiainhepatitiscvirusgenotype3patients